A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study

D. S. Ettinger; R. Day; J. A. Ferraro; J. C. Ruckdeschel; J. E. Woll; R. H. Creech; S. E. Vogl

doi:10.1097/00000421-198304000-00004

A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study

D. S. Ettinger, R. Day, J. A. Ferraro, J. C. Ruckdeschel, J. E. Woll, R. H. Creech, S. E. Vogl

School of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m² intravenously every 3 weeks or neocarzinostatin 2.0 mg/m² intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.

Original language	English (US)
Pages (from-to)	167-170
Number of pages	4
Journal	Unknown Journal
Volume	6
Issue number	2
DOIs	https://doi.org/10.1097/00000421-198304000-00004
State	Published - 1983

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-198304000-00004

Cite this

@article{9815ed4a26c74231babfe58e8cd4008f,

title = "A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study",

abstract = "Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.",

author = "Ettinger, {D. S.} and R. Day and Ferraro, {J. A.} and Ruckdeschel, {J. C.} and Woll, {J. E.} and Creech, {R. H.} and Vogl, {S. E.}",

year = "1983",

doi = "10.1097/00000421-198304000-00004",

language = "English (US)",

volume = "6",

pages = "167--170",

journal = "Advances in Water Resources",

issn = "0309-1708",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study

AU - Ettinger, D. S.

AU - Day, R.

AU - Ferraro, J. A.

AU - Ruckdeschel, J. C.

AU - Woll, J. E.

AU - Creech, R. H.

AU - Vogl, S. E.

PY - 1983

Y1 - 1983

N2 - Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.

AB - Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0020535590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020535590&partnerID=8YFLogxK

U2 - 10.1097/00000421-198304000-00004

DO - 10.1097/00000421-198304000-00004

M3 - Article

C2 - 6299093

AN - SCOPUS:0020535590

VL - 6

SP - 167

EP - 170

JO - Advances in Water Resources

JF - Advances in Water Resources

SN - 0309-1708

IS - 2

ER -

A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this